Predicting Early Mortality in Newly Diagnosed AL Amyloidosis: Development and Validation of the PACE Score for Daratumumab‐Treated Patients
American Journal of Hematology · 2026-04 · 101 (4) · 768-783
DOI: 10.1002/ajh.70257 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift American Journal of Hematology, online erschienen am 07.03.2026. Verfasst von George S Mellgard und 24 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Columbia University Irving Medical Center, New York, New York, USA. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Immunoglobulin Light-chain Amyloidosis. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 21 Literaturangaben.
Abstract (Originalsprache)
Systemic AL amyloidosis is a clonal plasma cell dyscrasia, where toxic free light chains (FLCs) lead to vital organ damage, with risk of early mortality despite effective therapies. Notably, there is a paucity of data on the incidence and predictors of early mortality in the daratumumab (Dara) era. We conducted a multi‐center retrospective cohort study to develop and validate a risk‐prediction model for early mortality (all‐cause death within 6 months) in patients treated with Dara‐based frontline regimens. We used univariate analysis to identify covariates for a logistic regression model predictive of 6‐month mortality and generated a clinical risk score. Among 339 patients across eight centers, 36 (10.6%) experienced early mortality. Multivariate analysis identified four independent predictors: NT‐proBN P > 5300 pg/mL (odds ratio [OR] 3.83, p = 0.006), A ge > 75 years (OR 2.96, p = 0.073), absence of t(11;14) on C ytogenetics (OR 3.0, p = 0.022), and E COG performance status (OR 1.72 per unit increase, p = 0.044). The resulting PACE score stratified patients into three risk groups with a 6‐month mortality of 1.2% (low‐risk), 11.7% (intermediate‐risk), and 50.0% (high‐risk). The PACE score demonstrated superior discrimination (C‐index 0.78) for early mortality compared to Mayo 2004 (0.69) and Mayo 2012 (0.55) staging systems. External validation confirmed robust discrimination (C‐index 0.73) with corresponding 6‐month mortality rates of 4.2%, 15.25%, and 37.04% across respective risk groups. The PACE score provides a clinically applicable tool for early mortality risk stratification in AL amyloidosis patients receiving Dara‐based therapy, and will enable improved patient counseling, clinical trial design, and identification of ultra‐high‐risk patients requiring intensive monitoring and novel therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Columbia University Irving Medical Center, New York, New York, USA.
- Department of Hematology/Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
- Columbia University Herbert Irving Comprehensive Cancer Center, New York, New York, USA.
- Sorbonne University, Service d'Hematologie Clinique et Thérapie Cellulaire, Hôpital Saint Antoine, and INSERM UMR 938, Paris, France.
- Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
- Medical Department V, Amyloidosis Center, University of Heidelberg, Heidelberg, Germany.
ORCID-Profile: Ute Hegenbart, Divaya Bhutani, Anita D'Souza, Morie Gertz, Giovanni Palladini, Vaishali Sanchorawala, Efstathios Kastritis, Foteini Theodorakakou, Rajshekhar Chakraborty
Zitieren
APA
Mellgard, G. S., Bazarbachi, A. H., Zanwar, S., Hegenbart, U., Bodanapu, G., Bhutani, D., Chen, G., D'Souza, A., Dispenzieri, A., Gertz, M., Kumar, S., Lentzsch, S., Milani, P., Muchtar, E., Palladini, G., Trajanova, D., Patwari, A., Sanchorawala, V., Mohty, M., …, & Cowan, A. J. (2026). Predicting Early Mortality in Newly Diagnosed AL Amyloidosis: Development and Validation of the PACE Score for Daratumumab‐Treated Patients. American Journal of Hematology, 101(4), 768-783. https://doi.org/10.1002/ajh.70257
Vancouver
Mellgard GS, Bazarbachi AH, Zanwar S, Hegenbart U, Bodanapu G, Bhutani D, et al. Predicting Early Mortality in Newly Diagnosed AL Amyloidosis: Development and Validation of the PACE Score for Daratumumab‐Treated Patients. American Journal of Hematology. 2026;101(4):768-783. doi:10.1002/ajh.70257
BibTeX
@article{Mellgard2026,
author = {Mellgard, George S and Bazarbachi, Abdul-Hamid and Zanwar, Saurabh and Hegenbart, Ute and Bodanapu, Geethika and Bhutani, Divaya and Chen, GuiZhen and D'Souza, Anita and Dispenzieri, Angela and Gertz, Morie and Kumar, Shaji and Lentzsch, Suzanne and Milani, Paolo and Muchtar, Eli and Palladini, Giovanni and Trajanova, Despina and Patwari, Anannya and Sanchorawala, Vaishali and Mohty, Mohamad and Wang, Shikun and Kastritis, Efstathios and Theodorakakou, Foteini and Schönland, Stefan and Chakraborty, Rajshekhar and Cowan, Andrew J},
title = {Predicting Early Mortality in Newly Diagnosed AL Amyloidosis: Development and Validation of the PACE Score for Daratumumab‐Treated Patients},
journal = {American Journal of Hematology},
year = {2026},
volume = {101},
number = {4},
pages = {768--783},
doi = {10.1002/ajh.70257}
}
EUVIMED